Literature DB >> 22627831

Analytical challenges and technical limitations in assessing circulating miRNAs.

Anna Zampetaki1, Manuel Mayr.   

Abstract

MiRNAs are emerging as promising biomarkers in cardiovascular diseases and may constitute a novel mechanism of intercellular communication. Accurate quantification of circulating miRNAs is essential. A variety of technological approaches and platforms have been developed with increased sensitivity and specificity for the detection and quantification of circulating miRNAs. In this review, we focus on the technical aspects and discuss the analytical challenges in profiling circulating miRNAs.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22627831     DOI： 10.1160/TH12-02-0097

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


  52 in total

Review 1.  Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma.

Authors:  Michela Bottani; Giuseppe Banfi; Giovanni Lombardi
Journal:  J Clin Med       Date:  2019-10-11       Impact factor: 4.241

Review 2.  microRNA-based diagnostics and therapy in cardiovascular disease-Summing up the facts.

Authors:  Christian Schulte; Tanja Zeller
Journal:  Cardiovasc Diagn Ther       Date:  2015-02

3.  Circulating microRNA biomarkers for cardiovascular risk prediction: are we approaching clinical application?

Authors:  Maurice W J de Ronde; Yigal M Pinto; Sara-Joan Pinto-Sietsma
Journal:  Ann Transl Med       Date:  2016-12

Review 4.  Future microfluidic and nanofluidic modular platforms for nucleic acid liquid biopsy in precision medicine.

Authors:  Ana Egatz-Gomez; Ceming Wang; Flora Klacsmann; Zehao Pan; Steve Marczak; Yunshan Wang; Gongchen Sun; Satyajyoti Senapati; Hsueh-Chia Chang
Journal:  Biomicrofluidics       Date:  2016-05-05       Impact factor: 2.800

5.  Evaluation of Serum Paired MicroRNA Ratios for Differential Diagnosis of Non-Small Cell Lung Cancer and Benign Pulmonary Diseases.

Authors:  Lihong Fan; Jie Sha; Junliang Teng; Dan Li; Changhui Wang; Qing Xia; Hao Chen; Bo Su; Huiwei Qi
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

Review 6.  miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives.

Authors:  Mateusz Florczuk; Adam Szpechcinski; Joanna Chorostowska-Wynimko
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

7.  Analysis of circulating microRNAs that are specifically increased in hyperlipidemic and/or hyperglycemic sera.

Authors:  Natalia Simionescu; Loredan S Niculescu; Gabriela M Sanda; Denisa Margina; Anca V Sima
Journal:  Mol Biol Rep       Date:  2014-06-14       Impact factor: 2.316

Review 8.  MicroRNAs in bone diseases.

Authors:  L Gennari; S Bianciardi; D Merlotti
Journal:  Osteoporos Int       Date:  2016-11-30       Impact factor: 4.507

Review 9.  Exploiting Circulating MicroRNAs as Biomarkers in Psychiatric Disorders.

Authors:  Bhaskar Roy; Yuta Yoshino; Lauren Allen; Kevin Prall; Grant Schell; Yogesh Dwivedi
Journal:  Mol Diagn Ther       Date:  2020-06       Impact factor: 4.074

Review 10.  Design and Analysis for Studying microRNAs in Human Disease: A Primer on -Omic Technologies.

Authors:  Viswam S Nair; Colin C Pritchard; Muneesh Tewari; John P A Ioannidis
Journal:  Am J Epidemiol       Date:  2014-06-24       Impact factor: 4.897
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.